Zerbaxa fda approval?

See the DrugPatentWatch profile for Zerbaxa

When was Zerbaxa approved by the FDA?

Zerbaxa (ceftolozane and tazobactam) received FDA approval in 2014 for treating complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) in adults. [1]

What is Zerbaxa (active ingredients and what it’s used for)?

Zerbaxa combines two active drugs: ceftolozane (a cephalosporin antibiotic) and tazobactam (a beta-lactamase inhibitor). It is used for specific serious bacterial infections where these organisms may be resistant to other antibiotics. [1]

Does Zerbaxa still have FDA indications for adults?

Yes. Zerbaxa’s FDA labeling includes treatment use in adults for complicated infections such as cUTI and cIAI, and additional approved use(s) are reflected in its FDA-approved label over time. [1]

Who makes Zerbaxa, and where can I check patent/exclusivity details?

If you’re looking up manufacturer and market-exclusivity or patent-related information, DrugPatentWatch tracks Zerbaxa-related filings and status. [2]

Sources

[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] https://www.drugpatentwatch.com/